top of page
Microscope

STUDIES

EPOXI

Start Date:

August 2024

Duration:

2 years

Sponsor:

UMCU

Registration Number:

NCT06156566

ID-CARE Role:

Monitor for Italian centres.

Description:

Phase IV European randomised clinical trial on mPOX Infection

RECOVERY

Start Date:

June 2024

Duration:

24 months

Sponsor:

European Commission

Registration Number:

NCT04381936

ID-CARE Role:

National Coordinator for Italy

Description:

Randomised Evaluation of COVID-19 Therapy

SOLIDACT

Start Date:

June 2021

Duration:

3 years

Sponsor:

University of Oslo

Registration Number:

NCT04891133

ID-CARE Role:

National Coordinator for Italy

Description:

An Adaptive Pandemic and Emerging Infection Platform Trial

PRUDENCE

Start Date:

March 2019

Duration:

5 years

Sponsor:

University of Oxford

Registration Number:

285877

ID-CARE Role:

Coordinator EU LTCF site

Description:

Platform Randomised controlled trial of point of care Diagnostics for Enhancing the quality of aNtibiotic prescribing for Community acquired acute respiratory tract infection in ambulatory care in Europe

POS-cUTI

Start Date:

January 2022

Duration:

4 years

Sponsor:

ECRAID

Registration Number:

NCT05458700

ID-CARE Role:

National coordinator for Italy.

Description:

Perpetual Observational Study on Complicated Urinary Tract Infections

SOLIDARITY

Start Date:

April 2020

Duration:

Sponsor:

WHO

Registration Number:

NCT04647669

ID-CARE Role:

National Coordinator for Italy

Description:

World Health Organization (WHO) COVID-19 Solidarity Trial for COVID-19 Treatments

MOSAIC

Start Date:

March 2023

Duration:

5 months

Sponsor:

University of Oxford

Registration Number:

2022-501132-42-00

ID-CARE Role:

Clinical center & National coordinator (Country Coordinator Center)

Description:

Cohort study of human Monkeypox virus disease

MANTICO

Start Date:

June 2021

Duration:

30 months

Sponsor:

AIFA

Registration Number:

NCT05205759, NCT05321394

ID-CARE Role:

National Coordinator for Italy

Description:

Clinical adaptive, randomized, controlled trial on monoclonal antibodies treatment for patients affected by light to moderate COVID-19 disease.

bottom of page